Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized biomarker-guided comparison of biologic modes of action in rheumatoid arthritis
2015-000581-58Phase 4Completed
- Sponsor
- Institute of Rheumatology
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab, abatacept, tocilizumab and rituximab in rheumatoid arthritis (RA) (4 arms), sponsored by Institute of Rheumatology. Primary endpoint: Absolute change in SDAI at 24 weeks. Started Jun 2015; status: completed.
02
Drugs
infliximababatacepttocilizumabrituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-000581-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000581-58.